Comprehensive review on Alzheimer's disease: causes and treatment

Z Breijyeh, R Karaman - Molecules, 2020 - mdpi.com
Alzheimer's disease (AD) is a disorder that causes degeneration of the cells in the brain and
it is the main cause of dementia, which is characterized by a decline in thinking and …

Protein misfolding, amyloid formation, and human disease: a summary of progress over the last decade

F Chiti, CM Dobson - Annual review of biochemistry, 2017 - annualreviews.org
Peptides and proteins have been found to possess an inherent tendency to convert from
their native functional states into intractable amyloid aggregates. This phenomenon is …

Cannabinoids: therapeutic use in clinical practice

C Pagano, G Navarra, L Coppola, G Avilia… - International journal of …, 2022 - mdpi.com
Medical case reports suggest that cannabinoids extracted from Cannabis sativa have
therapeutic effects; however, the therapeutic employment is limited due to the psychotropic …

[HTML][HTML] Interaction between Aβ and tau in the pathogenesis of Alzheimer's disease

H Zhang, W Wei, M Zhao, L Ma, X Jiang… - … journal of biological …, 2021 - ncbi.nlm.nih.gov
Extracellular neuritic plaques composed of amyloid‑β (Aβ) protein and intracellular
neurofibrillary tangles containing phosphorylated tau protein are the two hallmark proteins of …

Iron homeostasis disorder and Alzheimer's disease

Y Peng, X Chang, M Lang - International journal of molecular sciences, 2021 - mdpi.com
Iron is an essential trace metal for almost all organisms, including human; however,
oxidative stress can easily be caused when iron is in excess, producing toxicity to the human …

Epigallocatechin-3-Gallate (EGCG): New therapeutic perspectives for neuroprotection, aging, and neuroinflammation for the modern age

A Payne, S Nahashon, E Taka, GM Adinew… - Biomolecules, 2022 - mdpi.com
Alzheimer's and Parkinson's diseases are the two most common forms of neurodegenerative
diseases. The exact etiology of these disorders is not well known; however, environmental …

The immunosuppressive activity of artemisinin‐type drugs towards inflammatory and autoimmune diseases

T Efferth, F Oesch - Medicinal research reviews, 2021 - Wiley Online Library
The sesquiterpene lactone artemisinin from Artemisia annua L. is well established for
malaria therapy, but its bioactivity spectrum is much broader. In this review, we give a …

[HTML][HTML] Protective effects of luteolin against amyloid beta-induced oxidative stress and mitochondrial impairments through peroxisome proliferator-activated receptor γ …

Z He, X Li, Z Wang, Y Cao, S Han, N Li, J Cai, S Cheng… - Redox Biology, 2023 - Elsevier
Alzheimer's disease (AD) is a devastating neurodegenerative disorder characterized by the
deposition of β-amyloid (Aβ) peptides and dysfunction of mitochondrion, which result in …

Aducanumab therapy to treat Alzheimer's disease: a narrative review

SA Beshir, AM Aadithsoorya, A Parveen… - International Journal …, 2022 - Wiley Online Library
Background. Aducanumab, a new monoclonal antibody that targets β‐amyloid aggregates,
has been granted conditional approval by the US FDA for treatment of mild Alzheimer's …

Blood-brain barrier–penetrating siRNA nanomedicine for Alzheimer's disease therapy

Y Zhou, F Zhu, Y Liu, M Zheng, Y Wang, D Zhang… - Science …, 2020 - science.org
Toxic aggregated amyloid-β accumulation is a key pathogenic event in Alzheimer's disease
(AD), which derives from amyloid precursor protein (APP) through sequential cleavage by …